Allogene Therapeutics ALLO
NASDAQ ALLO
$1.97 -0.01 (-0.51%)
As of: Sep 4, 2026 · 3:59 PM EDT

Allogene Therapeutics (ALLO) EBITDA Margin Growth (1y) (2022 - 2024)

Analysis

Allogene Therapeutics (ALLO) EBITDA Margin Growth (1y) (2022 - 2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA Margin Growth (1y) (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -143.00
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 78.00
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 1,135.00
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 7,666.00
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 1,238.00
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 2,002.00
8 Royalty Pharma 28.45 Bn 27.61 Bn - -1,651.00
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 29,091.00
10 Allogene Therapeutics 647.99 Mn 647.99 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2024 1.44 Mn
Dec 31, 2023 -3.45 Mn
Sep 30, 2023 1.93 Mn
Jun 30, 2023 -24.64 Mn
Mar 31, 2023 -12.51 Mn
Dec 31, 2022 -37.08 Mn
Sep 30, 2022 -14.71 Mn
Jun 30, 2022 4.17 Mn
Mar 31, 2022 -20.51 Mn